Frequent subclinical macular changes in melanoma patients treated with combined BRAF/MEK inhibition and high dose hydroxychloroquine does not require dosing modification or discontinuation: preliminary results from a multi-institutional phase I/II clinical treatment trial for advanced metastatic BRAF mutant melanoma
Year: 2017
Type: article
Language: English
Topic: Drug-Induced Ocular Toxicity
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,850
OpenAlex ID: W2742010183
